GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » EV-to-EBITDA

Propanc Biopharma (Propanc Biopharma) EV-to-EBITDA : -0.53 (As of May. 11, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Propanc Biopharma's enterprise value is $1.00 Mil. Propanc Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.89 Mil. Therefore, Propanc Biopharma's EV-to-EBITDA for today is -0.53.

The historical rank and industry rank for Propanc Biopharma's EV-to-EBITDA or its related term are showing as below:

PPCB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -397.75   Med: 0   Max: 3.66
Current: -0.53

During the past 13 years, the highest EV-to-EBITDA of Propanc Biopharma was 3.66. The lowest was -397.75. And the median was 0.00.

PPCB's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs PPCB: -0.53

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Propanc Biopharma's stock price is $0.001. Propanc Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.625. Therefore, Propanc Biopharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Propanc Biopharma EV-to-EBITDA Historical Data

The historical data trend for Propanc Biopharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma EV-to-EBITDA Chart

Propanc Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.83 -0.84 -0.87 -0.60

Propanc Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -0.79 -0.60 -0.54 -0.73

Competitive Comparison of Propanc Biopharma's EV-to-EBITDA

For the Biotechnology subindustry, Propanc Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Propanc Biopharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's EV-to-EBITDA falls into.



Propanc Biopharma EV-to-EBITDA Calculation

Propanc Biopharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.998/-1.886
=-0.53

Propanc Biopharma's current Enterprise Value is $1.00 Mil.
Propanc Biopharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Propanc Biopharma  (OTCPK:PPCB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Propanc Biopharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.001/-0.625
=At Loss

Propanc Biopharma's share price for today is $0.001.
Propanc Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.625.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Propanc Biopharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Propanc Biopharma (Propanc Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Executives
Josef Zelinger director 59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano officer: CFO & Secretary C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon director BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz director, officer: CEO, CFO, Secretary, Treasurer 1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146